1. Peter A. Friedman. Agents affecting mineral ion homeostasis and bone turnover. Goodman & Gilman’s: The Pharmacological Basis of Therapeutics.12th ed. New York, McGraw-Hill Medical 2011; Page -1293.
2. Briggs GG, Freeman RK, editors. A Reference Guide to Fetal and Neonatal Risk: Drugs in Pregnancy and Lactation. 10th ed. Philadelphia, PA: Wolters Kluwer Health; 2015. Page - 1259.
3. Vincenzo Savica, Domenico Santoro, Paolo Monardo, Agostino Mallamace & Guido Bellinghieri. Sevelamer carbonate in the treatment of hyperphosphatemia in patients with chronic kidney disease on hemodialysis: Therapeutics and clinical risk management. Aug 2008; [Accessed Nov 2 2020] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2621379/
4. Markus Ketteler, Marianne Rix, Stanley Fan, Nicholas Pritchard, Ove Oestergaard, Scott Chasan Taber, Jeremy Heaton, Ajay Duggal and Philip A. Kalra. Efficacy and Tolerability of Sevelamer Carbonate in Hyperphosphatemic Patients Who Have Chronic Kidney Disease and Are Not on Dialysis. Clinical society of the American journal of nephrology, July 2008; https://cjasn.asnjournals.org/content/clinjasn/3/4/1125.full.pdf
5. Mylan Hungary, Electronic Medicines Compendium (EMC); [Revised June 6, 2019] [Accessed Nov 2, 2020] https://www.medicines.org.uk/emc/files/pil.8784.pdf
6. Genzyme Corporation, 2000; U.S. Food & Drug Administration; [Accessed Nov 2, 2020] https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022127s011lbl.pdf